| 000 | 01822 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250518010833.0 | ||
| 264 | 0 | _c20190218 | |
| 008 | 201902s 0 0 eng d | ||
| 022 | _a1935-5548 | ||
| 024 | 7 |
_a10.2337/dc18-0755 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMenon, Venu | |
| 245 | 0 | 0 |
_aFasiglifam-Induced Liver Injury in Patients With Type 2 Diabetes: Results of a Randomized Controlled Cardiovascular Outcomes Safety Trial. _h[electronic resource] |
| 260 |
_bDiabetes care _c12 2018 |
||
| 300 |
_a2603-2609 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aBenzofurans _xadverse effects |
| 650 | 0 | 4 |
_aCardiovascular Diseases _xepidemiology |
| 650 | 0 | 4 |
_aCardiovascular System _xmetabolism |
| 650 | 0 | 4 |
_aChemical and Drug Induced Liver Injury _xepidemiology |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xcomplications |
| 650 | 0 | 4 |
_aDiabetic Angiopathies _xepidemiology |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypoglycemic Agents _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aSulfones _xadverse effects |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aLincoff, A Michael | |
| 700 | 1 | _aNicholls, Stephen J | |
| 700 | 1 | _aJasper, Susan | |
| 700 | 1 | _aWolski, Kathy | |
| 700 | 1 | _aMcGuire, Darren K | |
| 700 | 1 | _aMehta, Cyrus R | |
| 700 | 1 | _aRosenstock, Julio | |
| 700 | 1 | _aLopez, Claudia | |
| 700 | 1 | _aMarcinak, John | |
| 700 | 1 | _aCao, Charlie | |
| 700 | 1 | _aNissen, Steven E | |
| 773 | 0 |
_tDiabetes care _gvol. 41 _gno. 12 _gp. 2603-2609 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2337/dc18-0755 _zAvailable from publisher's website |
| 999 |
_c29073903 _d29073903 |
||